Clinical trials recruiting in Richardson, Texas

Phase breakdown

Conditions recruiting in Richardson, Texas

Recruiting trials in Richardson, Texas

• 52-week Open Label Safety-Tolerability Study
  NCT07369154 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
  NCT07459647 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
  NCT07286175 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
  NCT07734493 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female)
• A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
  NCT05208762 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
  NCT07615426 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female)
• A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
  NCT06696755 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
  NCT07145918 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
  NCT07276997 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
  NCT06929273 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
  NCT07300969 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
  NCT07140913 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
  NCT06951698 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
  NCT06951711 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
  NCT07065240 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
  NCT06894212 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
  NCT04858334 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
  NCT06096844 · Phase: Phase 3 · Ages: 70 Years and older · Sex: All (male and female)
• Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
  NCT05181826 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
  NCT05174169 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
  NCT06830044 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
  NCT06216301 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
  NCT03851445 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
  NCT07494305 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
  NCT04181060 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
  NCT07173751 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Randomized Withdrawal Study in Patients With Schizophrenia
  NCT06961968 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
  NCT07686263 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
  NCT03418961 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
  NCT05184335 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
  NCT03678025 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
  NCT05850689 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
  NCT07565428 · Phase: Phase 3 · Ages: 18 Years to 55 Years · Sex: All (male and female)
• Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
  NCT06808984 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
  NCT07680946 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female)
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
  NCT06632977 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
  NCT05863195 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
  NCT06931340 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
  NCT04267848 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
  NCT03866382 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
  NCT07028853 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
  NCT04423211 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
  NCT05958381 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Richardson, Texas?

44 recruiting trials have at least one study site in Richardson, Texas.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.